e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Pulmonary circulation: animal models and experimental treatments
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Therapeutic potential of DMHCA for pulmonary arterial hypertension (PAH)
L. Taraseviciene-Stewart, M. Leberl, Z. Moumen, R. Kadam, U. Kompella, M. Zamora, A. Kratzer (Aurora, United States Of America)
Source:
Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Session:
Pulmonary circulation: animal models and experimental treatments
Session type:
Poster Discussion
Number:
492
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Taraseviciene-Stewart, M. Leberl, Z. Moumen, R. Kadam, U. Kompella, M. Zamora, A. Kratzer (Aurora, United States Of America). Therapeutic potential of DMHCA for pulmonary arterial hypertension (PAH). Eur Respir J 2013; 42: Suppl. 57, 492
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Human apyrase (APT102) treatment attenuates the development of severe pulmonary arterial hypertension (PAH)
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Role of survivin in experimental models of pulmonary arterial hypertension
Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside
Year: 2016
Formation of typical vascular lesions in a new experimental model of pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Renal denervation reduces pulmonary vascular remodeling in two experimental pulmonary arterial hypertension models
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Erythropoietin recapitulates hemodynamic features of hypoxia-induced pulmonary hypertension in mice
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
Expression and function of aquaporin 1 in hypoxia-induced pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: promising small molecules
Year: 2015
Targeting aquaporin 1 reverses hypoxia-induced pulmonary hypertension in mice
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
Intact serotonin signaling is not required for the development of severe angioproliferative pulmonary hypertension in rats
Source: International Congress 2014 – Pathobiology of pulmonary hypertension
Year: 2014
Pulmonary Function and response to treatment in pulmonary arterial hypertension (PAH)
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016
Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: basic science
Year: 2013
Prolonged activity of inhaled treprostinil prodrug nanoparticles in a rat model of pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Role of the TrkA receptor in experimental severe pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: promising small molecules
Year: 2015
Epidemiological and Clinical aspects of pulmonary arterial hypertension (PAH)
Source: International Congress 2018 – Clinical aspects of pulmonary hypertension
Year: 2018
LATE-BREAKING ABSTRACT: Pneumonectomy combined with SU5416: a novel animal model of pulmonary hypertension
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Role of microRNA 17/92 cluster and microRNA 21 in the pathogenesis of pulmonary hypertension – Novel therapeutic targets
Source: Annual Congress 2013 –Pulmonary circulation: basic science
Year: 2013
Pregnancy and pulmonary arterial hypertension (PAH)
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II
Year: 2013
Macitentan for pulmonary arterial hypertension (PAH): Early clinical experience of 94 patients
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015
Analysis of pulmonary endothelial microparticles, haemodynamics and functional class in pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Effect of POL6014, a protein epitope mimetic (PEM) neutrophil elastase inhibitor, in a model of monocrotaline (MCT)-induced pulmonary arterial hypertension in rats
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Repeated embolization and fibrinolysis inhibition induce chronic thromboembolic pulmonary hypertension in rabbits
Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept